Cumberland Sells Branded Drugs for $100 Million to Apotex Subsidiary
CPIX•Apotex subsidiary acquired Cumberland’s branded U.S. pharmaceuticals for $100 million in cash, approved by over 99% of shareholders at closing. Proceeds strengthen Cumberland’s balance sheet and refocus the company on its late-stage ifetroban pipeline targeting Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis and cancer metastasis.
1. Transaction Closing and Terms
Cumberland Pharmaceuticals closed its strategic transaction with an Apotex subsidiary on July 1, receiving $100 million in cash for its branded U.S. pharmaceutical portfolio. Shareholders approved the sale with over 99% of votes, transferring all marketed products and related rights to the buyer at closing.
2. Financial Position and Strategic Focus
The $100 million infusion bolsters Cumberland’s balance sheet and reduces operational overhead related to its established marketed brands. Management intends to redeploy capital toward late-stage clinical programs, narrowing its business model to focus solely on innovative rare disease therapies.
3. Ifetroban Pipeline Programs
Cumberland retains majority ownership of Cumberland Emerging Technologies and concentrates on ifetroban, a thromboxane antagonist in Phase II trials for Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis and cancer metastasis. The Duchenne cardiomyopathy program holds FDA Orphan Drug and Fast Track designations, with top-line data anticipated in the coming quarters.
